The cAMP pathway and the control of adrenocortical development and growth
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
In the last 10 years, extensive studies showed that the cAMP pathway is deregulated in patients suffering from adrenocortical tumours, and particularly in primary pigmented nodular adrenocortical disease (PPNAD). Here we describe how evidence arising from the analysis of patients’ data, mouse models and in vitro experiments, have shed light on the cAMP pathway as a central player in adrenal physiopathology. We also show how novel data generated from mouse models may point to new targets for potential therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kirschner, L. S., Carney, J. A., Pack, S. D., Taymans, S. E., Giatzakis, C., Cho, Y. S., Cho-Chung, Y. S., & Stratakis, C. A. (2000) · Nature Genetics · doi:10.1038/79238 · Cited by 1,153 · cited 2×
“Both PRKAR1A mutations (Bertherat et al., 2009; Kirschner et al., 2000) and PDE mutations (Horvath et al.”
BackgroundSelf-citationTissier, F., Cavard, C., Groussin, L., Perlemoine, K., Fumey, G., Hagneré, A.-M., René-Corail, F., Jullian, E., Gicquel, C., Bertagna, X., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0593 · Cited by 474 · cited 2×
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript frequently detected in both adrenocortical adenomas and carcinomas (Bonnet et al., 2011; Gaujoux et al., 2011; Tissier et al., 2005).”
BackgroundArakane, F., King, S. R., Du, Y., Kallen, C. B., Walsh, L. P., Watari, H., Stocco, D. M., & Strauss, J. F. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.51.32656 · Cited by 391 · cited 1×
“Interestingly, StAR, which is responsible for the limiting step of cholesterol transport into the mitochondria, is also directly activated by PKA phosphorylation (Arakane et al., 1997).”
BackgroundHorvath, A., Boikos, S., Giatzakis, C., Robinson-White, A., Groussin, L., Griffin, K. J., Stein, E., Levine, E., Delimpasi, G., Hsiao, H. P., et al. (2006) · Nature Genetics · doi:10.1038/ng1809 · Cited by 352 · cited 5×
“Consequently, the corresponding wild-type proteins are absent from the tumours (Groussin et al., 2002; Horvath et al., 2006a).”
BackgroundSelf-citationDoghman, M., Wakil, A. E., Cardinaud, B., Thomas, E., Wang, J., Zhao, W., Peralta-Del Valle, M. H. C., Figueiredo, B. C., Zambetti, G. P., & Lalli, E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3970 · Cited by 221 · cited 1×
“Therefore, increased mTOR activity through loss of R1α could support adrenocortical tumour formation (Doghman et al., 2010).”
BackgroundKim, A. C., Reuter, A. L., Zubair, M., Else, T., Serecky, K., Bingham, N. C., Lavery, G. G., Parker, K. L., & Hammer, G. D. (2008) · Development · doi:10.1242/dev.021493 · Cited by 202 · cited 1×
“Targeting the early loss of Ctnnb1 gene (encoding β-catenin) in developing adrenocortical cells induces complete failure of adrenal at birth, while lowering the number of cells with βcatenin inactivation only affects cortical cell renewal in adults (Kim et al., 2008).”
BackgroundGaujoux, S., Grabar, S., Fassnacht, M., Ragazzon, B., Launay, P., Libé, R., Chokri, I., Audebourg, A., Royer, B., Sbiera, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2006 · Cited by 146
Gaujoux, S., Tissier, F., Groussin, L., Libé, R., Ragazzon, B., Launay, P., Audebourg, A., Dousset, B., Bertagna, X., & Bertherat, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0631 · Cited by 142 · cited 2×
“Interestingly, CTNNB1 gene somatic mutations have been found in adrenal tumours developing secondarily in patients with PPNAD, as well as in patients suffering from Carney complex (Gaujoux et al., 2008; Tadjine et al., 2008).”
BackgroundBonnet, S., Gaujoux, S., Launay, P., Baudry, C., Chokri, I., Ragazzon, B., Libé, R., René-Corail, F., Audebourg, A., Vacher-Lavenu, M.-C., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1885 · Cited by 133
Narasaka, T., Suzuki, T., Moriya, T., & Sasano, H. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(00)00445-7 · Cited by 109 · cited 9×
“This situation is reminiscent of both human foetal zone and human adult ZR (Dharia et al., 2004; Narasaka et al., 2001).”
BackgroundInfluentialDetection of somatic β-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD)
Tadjine, M., Lampron, A., Ouadi, L., Horvath, A., Stratakis, C. A., & Bourdeau, I. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03273.x · Cited by 108 · cited 2×
“Interestingly, CTNNB1 gene somatic mutations have been found in adrenal tumours developing secondarily in patients with PPNAD, as well as in patients suffering from Carney complex (Gaujoux et al., 2008; Tadjine et al., 2008).”
BackgroundSelf-citationMapes, S., Corbin, C. J., Tarantal, A., & Conley, A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.9.6105 · Cited by 86 · cited 2×
“ZR is characterised by DHEA/DHEAS production that requires the presence of CYP17, but is also favoured by low 3βHSD expression (3βHSD competes for pregnenolone, the substrate CYP17 metabolizes into 17-hydroxypregnenolone) and high CYTB5 levels (that facilitates the 17–20 lyase activity of CYP17 to transform 17-hydroxy…”
BackgroundChung, T. T., Webb, T. R., Chan, L. F., Cooray, S. N., Metherell, L. A., King, P. J., Chapple, J. P., & Clark, A. J. L. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1744 · Cited by 82 · cited 2×
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript These mouse phenotypes reflect what is seen in human with Familial Glucocorticoid deficiency type 1, a disease mostly resulting from mutations in MC2R that impair its trafficking to the membrane (Chung et al., 2008).”
Background
Cited by
Di Dalmazi, G., Kisker, C., Calebiro, D., Mannelli, M., Canu, L., Arnaldi, G., Quinkler, M., Rayes, N., Tabarin, A., Laure Jullié, M., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2152 · Cited by 119
“lation of steroidogenesis in adrenocortical cells (18).”
Adrenocortical zonation, renewal, and remodeling
Pihlajoki, M., Dörner, J., Cochran, R. S., Heikinheimo, M., & Wilson, D. B. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00027 · Cited by 114
“cAMP binds to the regulatory subunits of PKA, allowing the catalytic subunits of protein kinase A (PKA) to phosphorylate downstream effectors, including transcription factors that enhance expression of steroidogenic genes (38).”
Influential60 YEARS OF POMC: Adrenal and extra-adrenal functions of ACTH
Gallo-Payet, N. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0257 · Cited by 98
Multiple aberrant hormone receptors in Cushing’s syndrome
Ghorayeb, N. E., Bourdeau, I., & Lacroix, A. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0200 · Cited by 90
Primary bilateral macronodular adrenal hyperplasia
De Venanzi, A., Alencar, G. A., Bourdeau, I., Fragoso, M. C. B. V., & Lacroix, A. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000061 · Cited by 73
“The chronic in-vitro administration of ACTH increases MC2R expression in adrenal cells, while acute stimulation causes internalization of the receptor [29,41].”
Background
Metadata
- Authors
- de Joussineau, C., Sahut-Barnola, I., Levy, I., Saloustros, E., Val, P., Stratakis, C. A., & Martinez, A.
- Venue
- Molecular and Cellular Endocrinology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 351
- Issue
- 1
- Pages
- 28-36
- ISSN
- 0303-7207 (ISSN-L)
- OpenAlex
- W1975896078
- Cited by
- 62
- References
- 13
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.